Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana

Shots:

• The Louisiana Department of Health signs a 5 years agreement with Asegua to implement the innovative payment model for the treatment of Hepatitis C and to improve the health of Louisiana citizens
• The innovative payment model allows the state of Louisiana to get an unlimited amount of Asegua’s authorized generic of Epclusa (sofosbuvir/velpatasvir) to treat patients within Louisiana’s Medicaid and Department of Corrections populations and caps the State’s medication costs
• Epclusa is a fixed-dose combination therapy indicated for the treatment of Hepatitis C genotype 1, 2, 3, 4, 5, or 6 infections with or without cirrhosis

Click here to read full press release/ article | Ref: Gilead | Image: Kratom Sciences